Will we get more simultaneous publications this year than last year at #KidneyWk? We had 16 last year @brendonneuen.bsky.social @nephroseeker.medsky.social Will thread all later - but the #NephJC blog will have them all

And @brendonneuen.bsky.social with another simultaneous pub in @jama.com jamanetwork.com/journals/jam... Flozination by GFR/albuminuria #KidneyWk

In the afternoon another late breaking oral session among other things at 4:30 pm @brendonneuen.bsky.social Lorundrostat A new oral GLP1 REMODEL to understand sema mechanism GBD kidney disease with @paddymark.bsky.social And @cervantes-lily1.bsky.social ! #KidneyWk

Is it not really TGF - and something else in the tubules? Fascinating Biomarker study in @ajkd.bsky.social from the EMPA-KIDNEY group www.ajkd.org/article/S027... cc @pranavgarimella.bsky.social #NephSky #RevengeOfTheTubules

New episode of Freely Filtered with @brendonneuen.bsky.social @hswapnil.medsky.social @captainchloride.bsky.social @sophia-kidney.bsky.social and author Muth Vaduganathan discussing the CONVINCE trial www.nephjc.com/freelyfilter... With chapters, refs, and pictures

And three ‘late breaking research’ orals each evening Thursday - Saturday #KidneyWk

A second High Impact trial session in plenary hall on Saturday AM #KidneyWk

It’s all live now! Apart from the two trials mentioned above We have 5 more sessions at #KidneyWk + posters High Impact Trials 1 on Friday AM in plenary hall

The opening plenary at #KidneyWk looks phenomenal Renal RCT Renaissance is upon us (LBCT list drops tomorrow) www.asn-online.org/education/ki...

In this house we drink liquids and support #nephjc (Maybe I should get a backpack next time) Donate at: www.nephjc.com/news/2025/9/...

Take the ultimate deep dive in major recent clinical trials with the largest global gathering of clinical trials key stakeholders at #CVCT2025, December 8-10, 2025 in Washington DC ! Discover the scientific program here: www.globalcvctforum.com/scientific-p... #clinicaltrials #clinicalresearch #CVCT

Join us December 8-10, Washington DC! Full programme here: www.globalcvctforum.com/scientific-p...

Interesting slide #BucketOfColdWater

📢 New in CJASN: pooled analysis of all completed phase 2/3 RCTs in #IgAN 🔹 4 drug classes (steroids, B-cell, complement, non-immunological) 🔹 All ↓ proteinuria ≥30% 🔹 All improved GFR slope 🔹 Biggest benefit: B-cell therapies journals.lww.com/cjasn/abstra...

If you want to support #NephJC and get some cool merch, check out www.nephjc.com/merch...#NephJC

Attending Kidney Week 2025? Check out details about the plenaries. We'll be there, at Booth 2234! #kidneywk #nephrology #nephsky @asnkidney.bsky.social www.docwirenews.com/post/asn-rev...

Your abstract could be next to inspire change in kidney care. When you share your research at #ISNWCN, the benefits go far beyond the presentation. • Global visibility • Peer recognition • Publication opportunity Submit your abstract today ➡️ http://lite.spr.ly/6...#ISNWCN,

😎Check out the VA for HiLO by @sejalplakhani.bsky.social 🆒 This should be quite the discussion, don't miss it! #NephJC #NephSky www.nephjc.com/news/2025/8/4/the-hilo-trial-visual-abstract

🌏 Join us at WCN'26 in Yokohama! 🧠 Learn from global experts 📈 Share your research 👥 Connect with peers 📅 Abstracts due Oct 22 🎬 #ISNFilmEvent submissions by Nov 5 ✈️ Travel grants & registration open Sept 16 🔗 http://lite.spr.ly/6...#ISNFilmEvent#ISNWCN

SGLT2i in CKD: impact beyond kidneys 🔻 15% all-cause hospitalizations ✅ Consistent regardless of eGFR, UACR & diabetes 🏥 ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems Meta-analysis in @asnpublications.bsky.social journals.lww.com/cjasn/pages/...

Only reason to sequence the RASi first is that they are good antihypertensives (but note the BP effect in the combo arm of #confidence) #nephjc But no matter the sequence, the goal should be to have someone on the four pillars in less than 6 months

@nephjc.bsky.social joining late, hi everyone 👋 nephrologist in Sydney, exec committee member of FIND-CKD, consult to both BI and Bayer and a number of other similar companies

Check out the Kidney Compass 🎙️ from @brendonneuen.bsky.social and Shikha Wadhwani with Rajiv Agarwal on CONFIDENCE podcasts.apple.com/ca/podcast/k... Prep for #NephJC tonight

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy doi.org/10.1016/j.kint.2025.05.028 #OpenAccess #IgAN #felzartamab #IgANephropathy

Following on CONFIDENCE (on #NephJC tomorrow) The design and baseline data from MIRO-CKD trial academic.oup.com/ndt/advance-... N = 614, balcinerone, dapagliflozin Urine ACR outcome #NephSky

We don’t get to discuss every important study that comes out on #NephJC Hence #NephJCShorts www.nephjc.com/news/nephjc-...

The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions ✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads www.nephjc.com/news/nephjc-... #MedSky #NephSky

From Rivka Galchen’s article in @newyorker.com: “The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.” And that’s how I’m going to explain it from now on.

In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk #ERA25 #MedSky #Nephrology

Huge Danish trial of nudges Patient level (N 22,000) + practice level (1500 practice cluster with N 28,000 pts) To increase RASination & Flozination www.ahajournals.org/doi/abs/10.1... in @ahajournals.bsky.social at #ERA25 Absolutely null effect - is the baseline too high to improve upon?

Baseline use of #SGLT2i in recent trials enrolling patients with #IgAN: Listen to the full podcast discussion between me, Shikha Wadwhani and Vlado Perkovic: hcplive.com/view/kidney-... #ERA25 #kidneycompass #sibeprenlimab #VISIONARY

Optimizing the timing and sequencing of guideline-directed medical therapy for T2D and CKD ca. 2024 from @brendonneuen.bsky.social #ERA25 🇦🇹 #Nephpearls #Cardiorenal #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40179265/

How will the #CONFIDENCE trial shape practice in #CKD + #T2D? I spoke with PI, Rajiv Agarwal, after his #ERA25 late-breaker on why a sequential approach may be doing our patients a disservice Full episode: hcplive.com/view/kidney-... #KidneyCompass #SGLT2i #finerenone

Inside story from PI Rajiv Agarwal: #CONFIDENCE done in 2 parts because of early safety concerns re simultaneous SGLT2i & nsMRA 🔹 Part A: higher GFR with ABPM after first dose 🔹 Part B: Main study without ABPM after 👍 from DSMB Full episode: www.hcplive.com/view/kidney-... #KidneyCompass #ERA25

The problem with starting one drug at a time is that the second drug never gets started Similar to the ‘time is now’ GDMT in HF, we need to overcome the therapeutic inertia and friction in the system @brendonneuen.bsky.social #NephSky #ERA25

Awesome late breaking clinical trials session II session #ERA25 @brendonneuen.bsky.social

It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25 journals.sagepub.com/doi/10.1177/...

By the way the #ERA25 hashtag is heating up Go check it out to get the science from Vienna and also find more fresh voices to follow! #NephSky

Sibeprenlimab inches closer to approval www.hcplive.com/view/fda-acc... feat @brendonneuen.bsky.social Phase 3 RCT next week at #ERA25 (& some journal?)

📅 Get ready for the next #NephJC on May 29 🧠💊 We’ll dive into: Lorundrostat for Uncontrolled Hypertension — efficacy, safety, and what it means for the future of BP management. ⏰ #NephSky #MedSKy @nejm.org www.nejm.org/doi/ful...

If someone is close to being on dialysis, I prefer to start dialysis before biopsy FWiW #NephJC

The ASIs have arrived www.nejm.org/doi/full/10.... Aldosterone synthase inhibitors - first one to finish the phase 3 line #Lorundrostat #Hypertension

New in CJASN: Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials @asnpublications.bsky.social: doi.org/10.2215/CJN....

Completely agree Patients with true resistant HT will likely be in sodium excess state and Spiro would make way more sense anyways Or Flozins Or a GLP1RA Depending on the clinical scenario But I 😍 the crisp PRECISION design #NephMadness

After sparsentan, another ERA gets accelerated approval on the basis of albuminuria while GFR slope data is being collected www.novartis.com/us-en/news/m... @nejm.org paper here www.nejm.org/doi/full/10.... #NephSky

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial Interesting data on discordance between cystatin and creatinine eGFR - In JACC: www.sciencedirect.com/science/arti...

Rationale and Design of NUDGE-CKD: A Nationwide Randomized Factorial Trial of Electronic Nudges for Increasing Guideline-Directed Medical Therapy in Chronic Kidney Disease From Tor Biering Sorensen and team in Copenhagen: www.sciencedirect.com/science/arti...

ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism #nephsky www.ahajournals.org/doi/10.1161/...

In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25 www.ahajournals.org/doi/abs/10.1...

Cardiovascular, Kidney & Mortality Outcomes With Long-Acting Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD progression ⬇️ 12% all-cause mortality diabetesjournals.org/care/article...